Moran Dvora, Quality and Laboratory Project Manager, Gsap, Israel, ECA Cannabis Working Group
Dr Joachim Erler, Auditor / QP, Blue Inspection Body, Germany
Dr Rainer Gnibl, GMP Inspector, District Government of Upper Bavaria, Germany
Dr Reinhard Kerker, GMP Inspectorate, Germany
Dr Andrea Kühn-Hebecker, Concept Heidelberg, Germany, ECA Cannabis Working Group
Luis Meirinhos Soares, GMP / GACP Inspector, Infarmed, Portugal
Sonny Moerenhout, CULTIVATORS, The Netherlands
Silja du Mont, GDP/GCP Inspectorate, Germany
Angela Müller, Senior Regulatory & Scientific Affairs Manager, Dr. Willmar Schwabe GmbH & Co. KG, Germany
Giorgia Tossi, Linnea, Switzerland
Dr Angel Valerio, EnWave, Canada
Dr Ingrid Walther, Pharma Consulting Walther, Germany, Leader of the ECA Cannabis Working Group
Dr John Zhang, EnWave, Canada
Medical cannabis has been permitted for prescription in Germany since 2017, causing a need for producers supplying pharmacists and physicians with the newly legalized drug. In addition, more and more countries around the world are following Germany by introducing programs in order to legalize cannabis for medical use. But what qualifies as medical grade cannabis? And which aspects have to be considered for CBD-Products? This conference will give you an overview of all relevant regulatory and GACP/GMP/GDP requirements and aspects for medical cannabis and CBD-Products.
In March 2017, the national German legislature expanded the options for prescribing medical cannabis products by passing a law amending provisions under the Narcotics Law and other regulations. These products, however, must comply with the relevant requirements laid down under Medicinal and Narcotics Law, including GACP/ GMP and GDP. Therefore, the BfArM (the Federal Institute for Drugs and Medical Devices) has taken over new responsibilities by establishing the Cannabis Agency. This agency is meant to help in ensuring supplies for medical-quality cannabis.
Unlike AGES in Austria, though, where cultivation of medical cannabis has already been established, cannabis will not be cultivated by BfArM itself, but by commissioned companies. Cannabis is not meant to be stored directly at BfArM during any stage of the purchasing, harvesting or distribution process. These steps will be carried out by relevant producers or other commissioned companies (i.e. suppliers, importers). Hence, the agency will manage and monitor the cultivation, harvest, processing, quality assurance, storage, packaging and distribution of cannabis to wholesalers, chemists or manufacturers.
The GMP inspectorates are responsible for issuing manufacturing and import licenses or GMP Certificates. Thus, they will perform inspections at the sites of manufacturers who apply for these certificates and licenses.
- The Cannabis Agency is responsible for ensuring that only medical grade cannabis is supplied,
- The relevant requirements based on the underlying legal framework (including Pharmacopoeias) and the corresponding GMP, GDP and GACP guidelines must be complied with, and finally
- Cannabis for medical purposes is also subject to the provisions of the Narcotics Law.
Non-EU suppliers, who currently produce according to GPP, will have to implement EU-GMP standards if they want to supply medical cannabis to the EU market. However, since there is currently no harmonized EU standard and pharmacopoeial monograph for medical cannabis (and extracts), national legislations, guidelines and pharmacopoeial monographs will have to be followed and applied in addition to EU-GMP.
This Live Online Conference addresses specific GMP aspects to consider for Growers, Manufacturers, Start-Ups, Suppliers, Importers, QPs and QA/QC personnel involved in Cannabis production and release. The topics provided are also of interest for GACP/ GMP/GDP Inspectors responsible for issuing a GMP certificate or manufacturers/import license.
For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.
At https://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because
of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.
Programme GACP Post-Conference - 24. November 2020
13.30 – 13.45 h Welcome and Introduction
13.45 – 14.45 h
The Intersection between GACP and GMP - View on the Inspection of Cannabis GACP and its Relation to GMP
- When does GACP end and (EU) GMP start?
- What will be checked during GACP and EU GMP inspections?
- Observations in inspections
- Open questions and issues to be solved
14.45 – 15.00 h Time for Discussion
15.00 – 15.15 h Coffee Break
15.15 – 16.00 h
GACP – Regulatory Information
- Herbal Drugs
- GACP vs. GMP
- Information in the Dossier
- Grower and Supplier
- Geographical source
- Herbal substance Manufacturing
16.00 – 16.30 h
GACP – Auditor´s View
- Cannabis Cultivation
- SOPs & records
- Expectations of a GACP auditor
16.30 – 16.45 h Time for additional Questions and Discussion
16.45 – 17.00 h Break
17.00 – 17.30 h
GACP – Grower´s / Supplier´s View
Growing medicinal cannabis is pharma, not food!
- The essence of cultivation under GACP
- Challenges and opportunities for growers within medicinal cannabis cultivation
- Practical implications for growers and suppliers
17.30 – 18.00 h Final Discussion